demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
secondary prevention
potential COVID-19 treatments
adjuvant therapies
anticoagulant
rivaroxaban MICHELLE

12 studies excluded by filtering options 2

5347 Mehra, 2020 2124excludednot a RCThigh risk of bias
5521 Del Amo, 2020 200excludedrisk of bias not avaialble
7070 PHE variants (Technical briefing 12 22 may 2021), 2021 2202excludednot a RCT
7420 PHE (Stowe), 2021 2133excludednot a RCThigh risk of bias
8149 PHE Technical briefing 16 (11/18 June 2021), 2021 2133excludednot a RCThigh risk of bias
8275 Musser, 2021 2130excludednot a RCTrisk of bias not avaialble
8350 Rosenberg, 2021 2130excludednot a RCTrisk of bias not avaialble
8515 Scobie, 2021 2200excludednot a RCTrisk of bias not avaialble
9170 UKHSA report 33 (23 december 2021), 2021 2200excludednot a RCTrisk of bias not avaialble
9176 UKHSA 31 december 2021, 2021 2200excludednot a RCTrisk of bias not avaialble
9214 Southern California (Lewnard), 2022 2130excludednot a RCTrisk of bias not avaialble
9294 UKHSA (report W4- 27 January), 2022 2120excludednot a RCTrisk of bias not avaialble